BEAM-conditioned autologous SCT improves the quality of response in Waldenström’s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre’s 10-year experience
- 2 June 2014
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 49 (9), 1231-1232
- https://doi.org/10.1038/bmt.2014.113
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Autologous Stem Cell Transplantation as a Care Option in Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2010
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemiaBone Marrow Transplantation, 2008
- Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patientsLeukemia, 2005
- Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.2005
- Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and CyclophosphamideLeukemia & Lymphoma, 2003